Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

The many vs. the few.

Loewenstein G.

Hastings Cent Rep. 2012 Sep-Oct;42(5):7-8; author reply 8-9. No abstract available.

PMID:
23050293
2.

The many vs. the few.

Wells RJ.

Hastings Cent Rep. 2012 Sep-Oct;42(5):7; author reply 8-9. No abstract available.

PMID:
23050292
3.

The many vs. the few.

Menzel PT.

Hastings Cent Rep. 2012 Sep-Oct;42(5):5-6; author reply 8-9. No abstract available.

PMID:
23050290
4.

Two dreams.

[No authors listed]

Hastings Cent Rep. 2012 Jan-Feb;42(1):2. No abstract available.

PMID:
22616382
5.

How should we model rare disease allocation decisions?

London AJ.

Hastings Cent Rep. 2012 Jan-Feb;42(1):3. No abstract available.

PMID:
22616383
6.

The many vs. the few.

McCabe C.

Hastings Cent Rep. 2012 Sep-Oct;42(5):6-7; author reply 8-9. No abstract available.

PMID:
23050291
7.

The many vs. the few.

Zallen DT.

Hastings Cent Rep. 2012 Sep-Oct;42(5):4-5; author reply 8-9. doi: 10.1002/hast.77. No abstract available.

PMID:
22976402
8.

Which orphans will find a home? The rule of rescue in resource allocation for rare diseases.

Largent EA, Pearson SD.

Hastings Cent Rep. 2012 Jan-Feb;42(1):27-34. No abstract available.

PMID:
22616398
9.

Reasonable disagreement about identified vs. statistical.

Daniels N.

Hastings Cent Rep. 2012 Jan-Feb;42(1):35-45. No abstract available.

PMID:
22616399
10.

Rationing of drugs for rare diseases.

Hughes D.

Pharmacoeconomics. 2006;24(4):315-6. No abstract available.

PMID:
16605277
11.

[Conference 1. An economic observatory for orphan drugs: myth or reality?].

Duguet C, Ferry A.

Med Sci (Paris). 2014 Apr;30 Spe(1):21-3. doi: 10.1051/medsci/201430s105. Epub 2014 Apr 14. French. No abstract available.

12.

How can the risk that orphan drugs present to budgets be managed better?

O'Neill C.

Clin Ther. 2010 Aug;32(9):1640-1. doi: 10.1016/j.clinthera.2010.08.007. No abstract available.

PMID:
20974321
13.

Rare diseases and effective treatments: are we delivering?

Luzzatto L, Hollak CE, Cox TM, Schieppati A, Licht C, Kääriäinen H, Merlini G, Schaefer F, Simoens S, Pani L, Garattini S, Remuzzi G.

Lancet. 2015 Feb 28;385(9970):750-2. doi: 10.1016/S0140-6736(15)60297-5. No abstract available.

PMID:
25752159
14.

Management of rare diseases.

Walshe JM.

QJM. 2006 Feb;99(2):123-4. Epub 2006 Jan 20. No abstract available.

15.

Orphan drugs revisited.

McCabe C, Tsuchiya A, Claxton K, Raftery J.

QJM. 2006 May;99(5):341-5; discussion 350-1. Epub 2006 Feb 27. No abstract available.

16.

Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.

John JE.

Drug Discov Today. 2011 Dec;16(23-24):999-1000. doi: 10.1016/j.drudis.2011.10.004. Epub 2011 Oct 14. No abstract available.

PMID:
22020052
17.

Adopting an orphan.

Rinaldi A.

EMBO Rep. 2005 Jun;6(6):507-10. No abstract available.

18.

[Orphan drugs: availability, reliability and reimbursement].

Kreeftmeijer-Vegter AR, van Veldhuizen CK, de Vries PJ.

Ned Tijdschr Geneeskd. 2012;156(17):A4252. Dutch.

PMID:
22531041
19.

Companies look for profit in orphan drugs.

Thompson CA.

Am J Health Syst Pharm. 2010 Nov 15;67(22):1892, 1895-6. doi: 10.2146/news100075. No abstract available.

PMID:
21048203
20.

Rare diseases, orphan drugs and their regulation: questions and misconceptions.

Tambuyzer E.

Nat Rev Drug Discov. 2010 Dec;9(12):921-9. doi: 10.1038/nrd3275. Epub 2010 Nov 9.

PMID:
21060315
Items per page

Supplemental Content

Write to the Help Desk